FLT3 and acute myeloid leukemia: Midostaurin (Rydapt; Novartis Pharmaceuticals Corporation), a FLT3 inhibitor with activity against other kinases, was approved by the FDA and EMA in 2017 in combination with cytarabine/daunorubicin chemotherapy for the treatment of adults with newly diagnosed, FLT3‐mutated AML (no upper age restrictions).36, 54